ICER Boosts ‘Cost-Recovery’ Benchmark Price For Remdesivir To Reflect Gilead’s Planned R&D

25 Jun 2020

But updated pricing model also suggests the more traditional ‘cost effectiveness’ benchmark price for remdesivir could be lower than previously estimated to account for use of dexamethasone in reducing the underlying risk of mortality in COVID-19 patients.

Coronavirus dollar bill — Price Modeling A Challenge In Rapidly Changing Environment

The Institute for Clinical and Economic Review has significantly increased its “cost recovery” benchmark price for Gilead Sciences Inc.’s antiviral remdesivir to account for the company’s planned research and development spending on the COVID-19 indication.

The revised price is now in the range of $1,010 to $1,600, ICER says in an updated report released 24 June. The initial version of the report estimated the cost recovery benchmark should be $10 for a 10-day course, which, controversially, reflected only the minimum manufacturing costs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

20 May 2025

• By Cathy Kelly

MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

20 May 2025

• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

20 May 2025

• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

15 May 2025

• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.